Skip to content
Open access

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Aug 2026 · The Oncologist · Vol 31 · 0 citations · 33 references
Medicine

TL;DR

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.

Abstract

Abstract Introduction Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC. Methods Eligible patients were ≥18 years old with advanced HCC, prior systemic therapy, Child-Pugh A-B7 liver function, ECOG 0-2, and FGF19 overexpression. Patients received futibatinib 20 mg orally daily plus pembrolizumab 200 mg intravenously every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints included overall survival (OS), objective response rate (ORR), quality of life, and safety. Results Between August 2021 and March 2024, 14 patients enrolled and 13 were evaluable. Median age was 72 years (range, 60-87), 53.8% were male, 92.3% had Child-Pugh A liver function, and all had received prior immunotherapy. Median progression-free survival was 15 weeks (95% CI, 9.0-NE), with a PFS6 rate of 23.1% (95% CI, 8.6-62.3%). ORR was 0% (95% CI, 0-24.7%), while stable disease was observed in 53.9% of patients. Median OS was 55.7 weeks (95% CI, 47.3-NE). Grade ≥3 adverse events occurred in 69.2% of patients, and grade ≥4 adverse events in 15.4%. One grade 5 event (acute-on-chronic kidney injury) was deemed unrelated to treatment. Common adverse events included hyperphosphatemia, fatigue, diarrhea, elevated transaminases, dry eye, nail changes, rash, and oral mucositis. Conclusions Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.

Read PDF

Similar papers

Open access Aug 2026

IUC25693-90 Real-world effectiveness of pembrolizumab plus axitinib in metastatic renal cell carcinoma in Panama

Abstract Background To evaluate the effectiveness and safety of pembrolizumab plus axitinib as first-line therapy for metastatic renal cell carcinoma (mRCC) in a national real-world cohort. This study is the first from Panama and the first from Central America to address this treatment strategy. Methods We conducted a...

J. Pinto, A. Cárdenas · 0 citations
Open access Sep 2026

Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program

Background Pembrolizumab–lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and...

D. B. Roufai, L. Mansi, M. H. Diallo et al. · 0 citations
Open access Sep 2026

Pemigatinib in the real-world management of advanced intrahepatic FGFR2-positive cholangiocarcinoma

Introduction. Cholangiocarcinoma (CC) is one of the most aggressive malignant tumors of the hepatobiliary tract with a poor prognosis, especially at the late stages. The targeted therapy with pemigatinib, a selective FGFR2 inhibitor, can be administered in a proportion (10–15%) of patients with intrahepatic cholangi...

M. Khagazheeva, A. R. Zaretsky, A. N. Koshmanova et al. · 0 citations
Open access Sep 2026

Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.

Relapsed or refractory lymphoma carries poor prognosis, with limited options after standard therapies. Spleen tyrosine kinase (SYK) mediates B-cell receptor and aberrant T-cell receptor signaling, promoting survival and proliferation. HMPL-523 (sovleplenib) is a novel, selective oral SYK inhibitor with preclinical acti...

P. Strati, D. Chraniuk, E. González Barca et al. · 0 citations
Open access Sep 2026

Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer

Abstract Background Pembrolizumab monotherapy is standard of care in first line treatment of patients with stage IV lung cancer and programmed death ligand 1 (PD-L1) expression ≥ 50%. Whether the higher levels of PD-L1 expression predict higher benefit from the treatment with pembrolizumab is still debatable. Patients...

V. Stojšić, B. Zarić, P. Simurdić et al. · 0 citations
Clinical trial Sep 2026

Clinical and Proteomic Biomarkers of Trifluridine/Tipiracil in Fluoropyrimidine-Refractory Advanced Pancreatic Adenocarcinoma: A Single-Arm Phase II Trial.

PURPOSE Patients with refractory pancreatic cancer have limited therapeutic option and dismal prognoses. This study aimed to evaluate the efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients with fluoropyrimidine-refractory pancreatic cancer and their predictive biomarkers. METHODS In this single-arm p...

Chi-Leung Chiang, S. Chan, A. Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.